Geoffrey Johnson, MD, PhD

Geoffrey Johnson, MD, PhD, is the Associate Director of the Mayo Clinic Comprehensive Cancer Center and Chair of the Radiopharmaceutical Trial Team. He is a Nuclear Medicine physician and a Radiologist.

Dr. Johnson is also the founder and Chief Scientific Officer of Nucleus RadioPharma, a CDMO for radiopharmaceutical development, production, and delivery.

Articles by Geoffrey Johnson, MD, PhD

CLARIFY Trial: Improved Prostate Cancer Outcomes with PSMA PET and Personalized Treatment

Geoffrey Johnson, MD, PhDProstate Cancer Diagnostics | October 10, 2024

The CLARIFY trial leveraged PSMA PET imaging for personalized prostate cancer treatment and detecting distant metastases.

CLARIFY Trial: Advancing PSMA PET Imaging for High-Risk Prostate Cancer Surgery

Geoffrey Johnson, MD, PhDProstate Cancer Diagnostics | October 10, 2024

Advanced PSMA PET imaging improved surgical outcomes for patients with high-risk prostate cancer in the CLARIFY trial.

Rationale, Dose Escalation for 67Cu-SAR-bisPSMA in Patients With mCRPC

Geoffrey Johnson, MD, PhDRLT | June 17, 2024

Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.